Supernus Pharmaceuticals SUPN EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Supernus Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's EBITDA margin?
- Supernus Pharmaceuticals (SUPN) reported EBITDA margin of 4.8% in Q1 2026.
- How has Supernus Pharmaceuticals's EBITDA margin changed year-over-year?
- Supernus Pharmaceuticals's EBITDA margin decreased by 79.4% year-over-year, from 23.1% to 4.8%.
- What is the long-term trend for Supernus Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's EBITDA margin has grown at a -35.6% compound annual growth rate (CAGR), from 36.9% to 4.1%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.